From: Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
a. SUCRA rankings for mortality | |
Treatment | SUCRA |
Sildenafil | 0.913 |
Pirfenidone | 0.749 |
Nintedanib | 0.719 |
Imatinib | 0.624 |
Macitentan | 0.604 |
Bosentan | 0.533 |
Placebo | 0.490 |
NAC monotherapy | 0.483 |
Ambrisentan | 0.238 |
VKA | 0.097 |
Triple therapy | 0.050 |
b. SUCRA rankings for severe adverse events | |
Treatment | SUCRA |
Bosentan | 0.756 |
Sildenafil | 0.692 |
Macitentan | 0.684 |
Nintedanib | 0.638 |
Imatinib | 0.627 |
Pirfenidone | 0.597 |
Placebo | 0.587 |
NAC monotherapy | 0.413 |
Ambrisentan | 0.279 |
VKA | 0.190 |
Triple therapy | 0.038 |